株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腎細胞癌:パイプライン製品の分析

Renal Cell Carcinoma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229738
出版日 ページ情報 英文 793 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
腎細胞癌:パイプライン製品の分析 Renal Cell Carcinoma - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 793 Pages
概要

腎細胞癌はかつては副腎腫とも呼ばれた腎臓癌の一種で、近位尿細管の裏層より発症します。主な症状として、血尿や腰腹痛、腹部腫瘤、倦怠感、体重減少・食欲不振、エリスロポエチン・赤血球増加症の抑制に伴う貧血症などが挙げられます。疾病素質には年齢や遺伝要因などがあります。化学療法や放射線治療により、この疾患を管理できる可能性があります。

当レポートでは、世界各国での腎細胞癌治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

腎細胞癌の概要

治療薬の開発

腎細胞癌:企業で開発中の治療薬

腎細胞癌:大学/機関で研究中の治療薬

腎細胞癌:パイプライン製品の概況

腎細胞癌:企業で開発中の製品

腎細胞癌:大学/機関で研究中の製品

腎細胞癌の治療薬開発に従事している企業

腎細胞癌:治療薬の評価

薬剤プロファイル

腎細胞癌:最近のパイプライン動向

腎細胞癌:休止中のプロジェクト

腎細胞癌:開発が中止された製品

腎細胞癌:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8682IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Renal Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Renal Cell Carcinoma (Oncology) pipeline landscape.

Renal cell carcinoma (RCC, formerly known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule. Symptoms include hematuria, loin pain, abdominal mass, malaise, which is a general feeling of feeling unwell, weight loss and/or loss of appetite, anemia resulting from depression of erythropoietin and erythrocytosis. The predisposing factors are age and hereditary factors. The disease is controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Renal Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Renal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 46, 42, 3, 34, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 3 and 4 molecules, respectively.Renal Cell Carcinoma.

Renal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Renal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Renal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Renal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Renal Cell Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Renal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Renal Cell Carcinoma Overview
  • Therapeutics Development
  • Renal Cell Carcinoma - Therapeutics under Development by Companies
  • Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Renal Cell Carcinoma - Pipeline Products Glance
  • Renal Cell Carcinoma - Products under Development by Companies
  • Renal Cell Carcinoma - Products under Investigation by Universities/Institutes
  • Renal Cell Carcinoma - Companies Involved in Therapeutics Development
  • Renal Cell Carcinoma - Therapeutics Assessment
  • Drug Profiles
  • Renal Cell Carcinoma - Dormant Projects
  • Renal Cell Carcinoma - Discontinued Products
  • Renal Cell Carcinoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Renal Cell Carcinoma, H2 2016
  • Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Renal Cell Carcinoma - Pipeline by AbbVie Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Renal Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2016
  • Renal Cell Carcinoma - Pipeline by Ambrx, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Apac Biotech Pvt Ltd, H2 2016
  • Renal Cell Carcinoma - Pipeline by arGEN-X BV, H2 2016
  • Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by ARMO Biosciences, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2016
  • Renal Cell Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H2 2016
  • Renal Cell Carcinoma - Pipeline by BIOCAD, H2 2016
  • Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2016
  • Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2016
  • Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Renal Cell Carcinoma - Pipeline by Boston Biomedical, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Renal Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016
  • Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Renal Cell Carcinoma - Pipeline by Cytune Pharma SAS, H2 2016
  • Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016
  • Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by Five Prime Therapeutics Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Gene Techno Science Co., Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Hemispherx Biopharma, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Renal Cell Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H2 2016
  • Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2016
  • Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2016
  • Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Immunomedics, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Incuron, LLC, H2 2016
  • Renal Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016
  • Renal Cell Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Johnson & Johnson, H2 2016
  • Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by KineMed, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2016
  • Renal Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by MedImmune LLC, H2 2016
  • Renal Cell Carcinoma - Pipeline by Medivation, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2016
  • Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Molecular Partners AG, H2 2016
  • Renal Cell Carcinoma - Pipeline by Mologen AG, H2 2016
  • Renal Cell Carcinoma - Pipeline by Monopar Therapeutics LLC, H2 2016
  • Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Nektar Therapeutics, H2 2016
  • Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2016
  • Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2016
  • Renal Cell Carcinoma - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Omeros Corporation, H2 2016
  • Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by OncoMax, H2 2016
  • Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Pharmacyclics Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by PsiOxus Therapeutics Limited, H2 2016
  • Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016
  • Renal Cell Carcinoma - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Renal Cell Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Renal Cell Carcinoma - Pipeline by TC BioPharm Limited, H2 2016
  • Renal Cell Carcinoma - Pipeline by Theravectys SA, H2 2016
  • Renal Cell Carcinoma - Pipeline by Tocagen Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2016
  • Renal Cell Carcinoma - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Renal Cell Carcinoma - Pipeline by X4 Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Renal Cell Carcinoma - Dormant Projects, H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..5), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..6), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..7), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..8), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..9), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..10), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..11), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..12), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..13), H2 2016
  • Renal Cell Carcinoma - Dormant Projects (Contd..14), H2 2016
  • Renal Cell Carcinoma - Discontinued Products, H2 2016
  • Renal Cell Carcinoma - Discontinued Products (Contd..1), H2 2016
  • Renal Cell Carcinoma - Discontinued Products (Contd..2), H2 2016
  • Renal Cell Carcinoma - Discontinued Products (Contd..3), H2 2016

List of Figures

  • Number of Products under Development for Renal Cell Carcinoma, H2 2016
  • Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top